Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs.
Verona Pharma stock last closed at $105.09, down 0.05% from the previous day, and has increased 363.77% in one year. It has overperformed other stocks in the Biotechnology industry by 4.31 percentage points. Verona Pharma stock is currently +467.75% from its 52-week low of $18.51, and -0.39% from its 52-week high of $105.50.
There are currently 681.06M VRNA shares outstanding. The market value of VRNA is $8.95B. In the last 24 hours, 2.19M VRNA shares were traded.
How to Buy Verona Pharma Stock
Wondering how to invest in Verona Pharma stock? Here's how.
Choose where to buy Verona Pharma stock: You need to choose an online brokerage, but don't worry - we've sifted through dozens of online brokerages and apps to help you choose where to buy Verona Pharma stock.
Create a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've selected.
Deposit money your brokerage account: Pick your payment method and add your information.
Research Verona Pharma stock: The Verona Pharma ticker symbol is VRNA. Is Verona Pharma stock a good investment? Should you buy shares of VRNA? How do VRNA's underlying business fundamentals look? Do top analysts think Verona Pharma is a good buy? Why has VRNA's stock price moved recently? (Hint: Our stock market analysis tools can help you understand if VRNA is a good stock to buy).
Execute your VRNA purchase: Decide if you will purchase VRNA shares at the current market price or use a limit order to purchase VRNA shares at a particular price.
Watch your VRNA investment: Create a watchlist to key updates about your position in Verona Pharma stock.
Step 1: Choose where to buy Verona Pharma stock
You will need an online brokerage account to access the NASDAQ market and buy VRNA shares.
A brokerage account enables you to buy and sell a number of investments, including stocks, bonds, mutual funds, and ETFs.
Our favorite brokerage: eToro
Based on our research, eToro is the best online stock brokerage. Here's why:
You can invest in stocks with 0% commissions: Invest without paying trading commissions.
Buy fractional shares: Even if you don't have the money to buy a full share, you can still purchase the stock.
Access to global financial markets: From Technology to Real Estate, New York to Hong Kong (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's top stock exchanges.
Social investing: eToro boasts a community of more than 20 million users globally. Talk to, learn from, and copy the crypto trades of other investors.
Security: eToro is a regulated and licensed fintech leader.
Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your share purchase by signing up for an account with eToro now. This offer is only for US users.
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.
Step 2: Create a brokerage account
Now that you've selected the right brokerage, the next step is to fill out some personal information so you are able to invest in VRNA today.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
Step 4: Research Verona Pharma stock
Once you have chosen the best place to buy Verona Pharma stock, it's very important to evaluate their stock before you buy, so you actually understand the risk and upside.
Verona Pharma stock at a glance
VRNA Price
$105.09
1w %
0.09%
1y %
363.77%
5y %
1,440.91%
P/E
-52.55x
P/B
39.48x
P/S
75.28x
PEG
N/A
Revenue
$118.54M
Earnings
-$163.94M
Fore. Rev. Growth
105%
Fore. Earn. Growth
N/A
Market Cap
$8.95B
Next Earnings
N/A
Next Dividend
N/A
Verona Pharma Due Diligence Score
WallStreetZen was created to help average investors do more accurate fundamental analysis.
There are more short-term assets than long-term liabilities on the VRNA balance sheet.
VRNA has $401.42M in cash and short term investments. This is sufficient to cover its annual cash burn of $121.25M.
There are more short-term assets than short-term liabilities on the VRNA balance sheet.
VRNA has cash burn of 121253000. It has enough cash and short-term investments to cover this for at least one year.
Failed Financial Due Diligence Checks:
VRNA has a relatively high debt to equity ratio of 1.32.
VRNA profit margin has gone down from N/A to -138.3% in the past year.
Total VRNA debt is higher than 5 years ago, relative to shareholder equity.
Is VRNA stock a Buy, Hold, or Sell, according to Wall Street analysts?
Out of 9 sell side analysts who give ratings on VRNA, the consensus analyst rating on Verona Pharma is a Buy
Please keep in mind that analyst ratings are not stock recommendations, nor are they investment advice.
Latest VRNA Analyst Recommendations
Yasmeen Rahimi, a top 5% analyst from Piper Sandler maintains VRNA with a strong buy rating and raises their VRNA price target from $76.00 to $160.00, on Jun 23, 2025.
Piper Sandler's Yasmeen Rahimi raised their price target on Verona Pharma (NASDAQ: VRNA) by 110.5% from $76 to $160 on 2025/06/23. The analyst maintained their Strong Buy rating on the stock.
Verona Pharma remains Piper Sandler's top sector pick for 2025, Rahimi told readers.
The analyst explained that they expect OHTUVAYRE to achieve blockbuster growth status in 2027 as it increasingly integrates into the Chronic Obstructive Pulmonary Disease therapy paradigm.
Boobalan Pachaiyappan, a top 27% analyst from Roth Capital reiterates VRNA with a strong buy rating and raises their VRNA price target from $92.00 to $116.00, on Jun 18, 2025.
Andrew Tsai, a bottom 6% analyst from Jefferies maintains VRNA with a strong buy rating and raises their VRNA price target from $95.00 to $110.00, on Jun 11, 2025.
Olivia Brayer, a top 33% analyst from Cantor Fitzgerald maintains VRNA with a strong buy rating and raises their VRNA price target from $90.00 to $100.00, on Jun 11, 2025.
An analyst from Jefferies maintains VRNA with a strong buy rating and maintains their VRNA price target from $95.00 to $95.00, on May 30, 2025.
Last year, VRNA revenue was $118.54M. Over the last 3 year, VRNA's revenue has gone up by 125.22% per year. This was faster than the Biotechnology industry average of 46.35%.
No, Verona Pharma doesn't provide an income stream by paying out dividends.
VRNA Social Trading Data
One of the biggest reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to learn what other investors have to say.
Step 5: Execute your VRNA purchase
There are two primary order types:
Market order: A market order is an order to buy or sell a stock at the best possible price. Market orders are usually the easiest way to buy.
Limit order: A limit order allows you to buy or sell a stock at a specific price (or better). If you want to be sure you're buying or selling at a given dollar amount limit, place a limit order.
Press the Open Trade button and eToro will place your order.
If you need additional info about buying stocks on eToro, watch the how to video below:
How much does it cost to buy one Verona Pharma share?
As of Jul 31, 2025, it costs $105.09 to buy one share of Verona Pharma stock.
Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $10, you can buy 0.095 shares of VRNA.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.